Can J Surg 2016;59(3):213-15 | PDF
Sarah E. Moore, MD; Katayoon Kasaian, PhD; Steven Jones, PhD; Adrienne Melck, MD; Sam M. Wiseman, MD
A cancer-related factor that is not included in papillary thyroid cancer (PTC) prognostic scoring systems is bilaterality. While it may seem that bilaterality should be considered during the management of PTC, its clinical importance has been debated. This controversy exists because the extent of surgery for PTC has not been found to affect survival in low-risk individuals, despite their potential for PTC bilaterality. We sought to determine if PTC bilaterality is a cancer prognosticator based upon its association with known clinical and pathological PTC prognosticators, and MACIS scores. In this article we discuss our findings and their potential clinical implications.
Accepted for publication Apr. 6, 2016
Affiliations: From the Department of Surgery, St. Paul’s Hospital and University of British Columbia, Vancouver, BC (Moore, Melck, Wiseman); the Michael Smith Genome Sciences Centre, British Columbia Cancer Research Centre, Vancouver, BC (Kasaian, Jones); and the Department of Medical Genetics, University of British Columbia, Vancouver, BC (Jones).
Competing interests: None declared.
Contributors: All authors contributed substantially to the conception, writing and revision of this article and approved the final version for publication.
Correspondence to: S.M. Wiseman, Department of Surgery, St. Paul’s Hospital & University of British Columbia, Rm. C303, Burrard Building, 1081 Burrard St., Vancouver, BC, V6Z 1Y6; firstname.lastname@example.org